Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.14 EUR | +0.64% | -1.26% | -3.09% |
2023 | Encres Dubuit Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
2023 | Encres Dubuit Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The stock, which is currently worth 2023 to 0.3 times its sales, is clearly overvalued in comparison with peers.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.09% | 10.2M | - | ||
+9.29% | 4B | D+ | ||
+5.18% | 1.75B | B+ | ||
+3.44% | 979M | D+ | ||
+9.13% | 966M | - | ||
+66.88% | 752M | - | - | |
-2.47% | 692M | - | - | |
+31.71% | 600M | B- | ||
-1.29% | 553M | - | ||
+15.68% | 499M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- ALDUB Stock
- Ratings Encres DUBUIT